2026 Q3 - tulosraportti
10 päivää sitten
‧27 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 250 | ||
| 26 | ||
| 724 | ||
| 76 | ||
| 2 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 5.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·13.10.I obviously have a different view on the information that the FDA has given Ascelia and regarding the way forward, than many here on Nordnet. I saw now, that someone had asked me a question, a while ago. I am a customer at Avanza and made many posts there, but also chosen to make posts in Nordnet. But am not logged in so often. Orviglance addresses a significant medical need that is currently unmet. No serious safety issues have been identified. Existing clinical studies provide evidence supporting Orviglance's technical performance as a contrast agent in T1-weighted magnetic resonance imaging. The above confirming statement from the FDA, which was included in Ascelia's press release, is crucial for a future partner. That the FDA confirms a significant medical need and that no serious safety issues have been identified are crucial messages for potential partners, who wanted to await more confirming news before they go further in the discussions. And Magnus spoke yesterday, on their "conference call", about this and the FDA's confirming information from the type-A meeting is confirming and positive for these stakeholders. That there is a way forward, without an entirely new study, is of course also positive. There have been stakeholders, even continuing after Ascelia's CRL. And I think it was clear after the latest quarterly report that Magnus clarified that they were still highly interested. What I took away with me yesterday, is that the partnership has now become much more actualized. I do not experience that Ascelia is just generally talking about a future partnership, but more concretely about the possibility to actually get an agreement in place. A coming agreement will, according to Magnus, also include the continued development work and future commercialization. I read an analyst who reasoned around it and of course it has an effect on the agreement's design. But Ascelia today stands with a product that the FDA has given confirmation to, in many of the ways that are of importance for future partners, the market, the company itself... so the FDA has pretty much given "an approval", except regulatory. I believe an agreement will be signed in the near future. About 3-5 months away, is my guess. And I think the management's conviction is also that a partnership will happen, within a not too distant future. Everyone interested, should listen to the "conference call", which was yesterday. I therefore see the partnership issue as a clear and possible trigger and absolutely believe something can happen there significantly more in the near term, than the market seems to calculate with. Stakeholders probably want to await the next FDA meeting, to get further clarification regarding one or two new endpoints. But I believe these stakeholders are also aware that this is window dressing. I believe the FDA just wants to try to bring about as trustworthy an exit as possible. It is at that level, that the FDA has placed it, the last year. Which has made companies that have submitted NDA/BLA applications, openly criticize the FDA, in a way that has not been done before. There has happened an enormous loss of confidence for the FDA. As I mentioned in previous posts, many FDA employees were laid off and many also chose to leave, in the political turmoil that arose. In a previous vote/survey made among biotech investors, the unpredictability that the FDA caused, was the biggest obstacle for the sector. "By late 2025, this rift had unnerved biotech investors so much that, in a survey conducted by RBC Capital Markets, nearly half of responders felt FDA volatility was the “biggest headwind.” The “multiple instances of reported regulatory flip-flopping” raise concerns that “may continue to pose a challenge to perceived investability,” wrote RBC analyst Brian Abrahams."
I think you are way too early out, in terms of concluding that the FDA "has pretty much given an approval" - I think they are quite a way from an approval!! Ascelia you are not the first small Nordic biotech that trips in some FDA threads.
12.10. · MuokattuThat was a very calm reaction to the news! A bit down , maybe, but for a pennystock it was marginal. Good support, good outlook - unless emmision comes. We have to wait and see. Given that price on bad news and hope was up to .9 sek - there is nothing preventing the stock to go further that that. I will repeat myself saying that FDA had a good reason to propose reuse og existing study - otherwise it would have been a bummer. Actually AI estimated chances for this outcome LOWER than request for complete new trail 25% vs 40% . Technology alone make this stock worth some real money.
Yes the share price is only set back to before 30 sep. So it is not that bad and completely expected.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
10 päivää sitten
‧27 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13.10.I obviously have a different view on the information that the FDA has given Ascelia and regarding the way forward, than many here on Nordnet. I saw now, that someone had asked me a question, a while ago. I am a customer at Avanza and made many posts there, but also chosen to make posts in Nordnet. But am not logged in so often. Orviglance addresses a significant medical need that is currently unmet. No serious safety issues have been identified. Existing clinical studies provide evidence supporting Orviglance's technical performance as a contrast agent in T1-weighted magnetic resonance imaging. The above confirming statement from the FDA, which was included in Ascelia's press release, is crucial for a future partner. That the FDA confirms a significant medical need and that no serious safety issues have been identified are crucial messages for potential partners, who wanted to await more confirming news before they go further in the discussions. And Magnus spoke yesterday, on their "conference call", about this and the FDA's confirming information from the type-A meeting is confirming and positive for these stakeholders. That there is a way forward, without an entirely new study, is of course also positive. There have been stakeholders, even continuing after Ascelia's CRL. And I think it was clear after the latest quarterly report that Magnus clarified that they were still highly interested. What I took away with me yesterday, is that the partnership has now become much more actualized. I do not experience that Ascelia is just generally talking about a future partnership, but more concretely about the possibility to actually get an agreement in place. A coming agreement will, according to Magnus, also include the continued development work and future commercialization. I read an analyst who reasoned around it and of course it has an effect on the agreement's design. But Ascelia today stands with a product that the FDA has given confirmation to, in many of the ways that are of importance for future partners, the market, the company itself... so the FDA has pretty much given "an approval", except regulatory. I believe an agreement will be signed in the near future. About 3-5 months away, is my guess. And I think the management's conviction is also that a partnership will happen, within a not too distant future. Everyone interested, should listen to the "conference call", which was yesterday. I therefore see the partnership issue as a clear and possible trigger and absolutely believe something can happen there significantly more in the near term, than the market seems to calculate with. Stakeholders probably want to await the next FDA meeting, to get further clarification regarding one or two new endpoints. But I believe these stakeholders are also aware that this is window dressing. I believe the FDA just wants to try to bring about as trustworthy an exit as possible. It is at that level, that the FDA has placed it, the last year. Which has made companies that have submitted NDA/BLA applications, openly criticize the FDA, in a way that has not been done before. There has happened an enormous loss of confidence for the FDA. As I mentioned in previous posts, many FDA employees were laid off and many also chose to leave, in the political turmoil that arose. In a previous vote/survey made among biotech investors, the unpredictability that the FDA caused, was the biggest obstacle for the sector. "By late 2025, this rift had unnerved biotech investors so much that, in a survey conducted by RBC Capital Markets, nearly half of responders felt FDA volatility was the “biggest headwind.” The “multiple instances of reported regulatory flip-flopping” raise concerns that “may continue to pose a challenge to perceived investability,” wrote RBC analyst Brian Abrahams."I think you are way too early out, in terms of concluding that the FDA "has pretty much given an approval" - I think they are quite a way from an approval!! Ascelia you are not the first small Nordic biotech that trips in some FDA threads.
- 12.10. · MuokattuThat was a very calm reaction to the news! A bit down , maybe, but for a pennystock it was marginal. Good support, good outlook - unless emmision comes. We have to wait and see. Given that price on bad news and hope was up to .9 sek - there is nothing preventing the stock to go further that that. I will repeat myself saying that FDA had a good reason to propose reuse og existing study - otherwise it would have been a bummer. Actually AI estimated chances for this outcome LOWER than request for complete new trail 25% vs 40% . Technology alone make this stock worth some real money.Yes the share price is only set back to before 30 sep. So it is not that bad and completely expected.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 250 | ||
| 26 | ||
| 724 | ||
| 76 | ||
| 2 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 5.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
10 päivää sitten
‧27 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 5.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13.10.I obviously have a different view on the information that the FDA has given Ascelia and regarding the way forward, than many here on Nordnet. I saw now, that someone had asked me a question, a while ago. I am a customer at Avanza and made many posts there, but also chosen to make posts in Nordnet. But am not logged in so often. Orviglance addresses a significant medical need that is currently unmet. No serious safety issues have been identified. Existing clinical studies provide evidence supporting Orviglance's technical performance as a contrast agent in T1-weighted magnetic resonance imaging. The above confirming statement from the FDA, which was included in Ascelia's press release, is crucial for a future partner. That the FDA confirms a significant medical need and that no serious safety issues have been identified are crucial messages for potential partners, who wanted to await more confirming news before they go further in the discussions. And Magnus spoke yesterday, on their "conference call", about this and the FDA's confirming information from the type-A meeting is confirming and positive for these stakeholders. That there is a way forward, without an entirely new study, is of course also positive. There have been stakeholders, even continuing after Ascelia's CRL. And I think it was clear after the latest quarterly report that Magnus clarified that they were still highly interested. What I took away with me yesterday, is that the partnership has now become much more actualized. I do not experience that Ascelia is just generally talking about a future partnership, but more concretely about the possibility to actually get an agreement in place. A coming agreement will, according to Magnus, also include the continued development work and future commercialization. I read an analyst who reasoned around it and of course it has an effect on the agreement's design. But Ascelia today stands with a product that the FDA has given confirmation to, in many of the ways that are of importance for future partners, the market, the company itself... so the FDA has pretty much given "an approval", except regulatory. I believe an agreement will be signed in the near future. About 3-5 months away, is my guess. And I think the management's conviction is also that a partnership will happen, within a not too distant future. Everyone interested, should listen to the "conference call", which was yesterday. I therefore see the partnership issue as a clear and possible trigger and absolutely believe something can happen there significantly more in the near term, than the market seems to calculate with. Stakeholders probably want to await the next FDA meeting, to get further clarification regarding one or two new endpoints. But I believe these stakeholders are also aware that this is window dressing. I believe the FDA just wants to try to bring about as trustworthy an exit as possible. It is at that level, that the FDA has placed it, the last year. Which has made companies that have submitted NDA/BLA applications, openly criticize the FDA, in a way that has not been done before. There has happened an enormous loss of confidence for the FDA. As I mentioned in previous posts, many FDA employees were laid off and many also chose to leave, in the political turmoil that arose. In a previous vote/survey made among biotech investors, the unpredictability that the FDA caused, was the biggest obstacle for the sector. "By late 2025, this rift had unnerved biotech investors so much that, in a survey conducted by RBC Capital Markets, nearly half of responders felt FDA volatility was the “biggest headwind.” The “multiple instances of reported regulatory flip-flopping” raise concerns that “may continue to pose a challenge to perceived investability,” wrote RBC analyst Brian Abrahams."I think you are way too early out, in terms of concluding that the FDA "has pretty much given an approval" - I think they are quite a way from an approval!! Ascelia you are not the first small Nordic biotech that trips in some FDA threads.
- 12.10. · MuokattuThat was a very calm reaction to the news! A bit down , maybe, but for a pennystock it was marginal. Good support, good outlook - unless emmision comes. We have to wait and see. Given that price on bad news and hope was up to .9 sek - there is nothing preventing the stock to go further that that. I will repeat myself saying that FDA had a good reason to propose reuse og existing study - otherwise it would have been a bummer. Actually AI estimated chances for this outcome LOWER than request for complete new trail 25% vs 40% . Technology alone make this stock worth some real money.Yes the share price is only set back to before 30 sep. So it is not that bad and completely expected.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 250 | ||
| 26 | ||
| 724 | ||
| 76 | ||
| 2 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt